MPAM
KRYS icon

Monarch Partners Asset Management’s Krystal Biotech KRYS Stock Holding History

Monarch Partners Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$4.27M Buy
53,905
+7,411
+16% +$550K 1.26% 15
2022
Q3 		$3.24M Buy
46,494
+31,719
+215% +$2.29M 0.97% 28
2022
Q2 		$970K Buy
+14,775
New +$919K 0.27% 131

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Monarch Partners Asset Management's KRYS Position: Q4 2022 in Review

Monarch Partners Asset Management increased its Krystal Biotech (KRYS) stake by 16% in Q4 2022, buying an estimated $550K and bringing the position to 53,905 shares worth $4.27M. The position accounts for 1.26% of the portfolio, ranked #15.

Monarch Partners Asset Management first reported a position in KRYS in Q2 2022 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold KRYS as of Q4 2022.

  • Monarch Partners Asset Management held 53,905 shares of Krystal Biotech worth $4.27M as of Q4 2022.
  • Monarch Partners Asset Management bought 7,411 Krystal Biotech shares in Q4 2022, an estimated $550K.
  • Krystal Biotech made up 1.26% of Monarch Partners Asset Management's portfolio in Q4 2022, its #15 holding.
  • Monarch Partners Asset Management first reported a position in Krystal Biotech in Q2 2022 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.